Red Light Holland Corp. (4YX.F)
| Previous close | 0.0314 |
| Open | 0.0300 |
| Bid | 0.0300 x N/A |
| Ask | 0.0420 x N/A |
| Day's range | 0.0300 - 0.0300 |
| 52-week range | 0.0280 - 0.0695 |
| Volume | |
| Avg. volume | 6,095 |
| Market cap | 12.757M |
| Beta (5Y monthly) | 1.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswirePharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
PharmAla will consult on GMP Drug Product and Regulatory Development for Red Light HollandVANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased that it has entered into a consulting relationship with Red Light Holland Corp. (“Red Light”), (CSE: TRIP) to consult
GlobeNewswireHuxley Health Inc. Provides Corporate Update - Appoints Bruce Linton as Chairman
TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Huxley Health Inc. (“Huxley” or the “Company”) is pleased to provide you with a comprehensive corporate update, highlighting significant milestones and developments that have shaped Huxley over the past year. Key Highlights: Acquisition of Sintalica Corp: Huxley strengthens its position in psychedelics-based treatments for Neuroinflammatory Disorders through the successful acquisition of Sintalica Corp.New Leadership: High profile additions creating a d
